BioNxt Shares Unmoved by Key Eurasian Patent Approval

BioNxt Solutions has secured a significant intellectual property milestone with the formal grant of a patent from the Eurasian Patent Organization (EAPO). Despite this strategic achievement for its multiple sclerosis treatment candidate, market participants have responded with notable indifference, leaving the company’s share price stagnant.

On November 20, BioNxt confirmed the official issuance of Patent No. 051510 by the EAPO. This intellectual property protection covers the company’s proprietary sublingual delivery platform for BNT23001, a thin-film formulation containing the active pharmaceutical ingredient Cladribin for managing multiple sclerosis. The innovative administration method involves placing the medication under the tongue, potentially offering patients a more convenient alternative to Read more...